patent expiry
saveDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))
community read0 votes
Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections
Data sources
globaldata
Found something off?
drug timeline · 1
same company · ±60 days · 3
- drug expirylaninamivir: Daiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))Apr 24, 2026
- phase 1 completionraludotatug deruxtecan: Daiichi Sankyo Co Ltd — raludotatug deruxtecan (Phase I Trial Completion)Apr 30, 2026
- approvalquizartinib dihydrochloride: VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — FDA approvalApr 13, 2026
comments(0)
5-min edit window · permanent after that